SynOx Therapeutics Ltd was founded in November 2020 and is solely focused on developing emactuzumab for the treatment of diffuse tenosynovial giant cell tumours (TGCT) and other indications. SynOx is backed by a strong investor syndicate with long and successful backgrounds in building biopharma companies.

Biotechnology

Health Care

Life Sciences

Pharmaceutical

Therapeutics

SynOx Therapeutics

SynOx Therapeutics' headquarters in Dublin City, Ireland

Raymond Barlow

Samuel Peedle

Robert Francomano

Frank Bracken

Sander Veltkamp

Sarah Clare

Broes Naeye

Description

People (1)

Frank Bracken

Jobs